Difference between revisions of "Fruquintinib (Elunate)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
| − | *2018-09: Approved for the treatment of patients with metastatic [[colorectal cancer]] | + | *2018-09: Approved for the treatment of patients with metastatic [[colorectal cancer|colorectal cancer (CRC)]] who have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan, including those who have previously received anti-VEGF therapy and/or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type). ''(Based on FRESCO)'' |
==Also known as== | ==Also known as== | ||
Revision as of 20:13, 7 November 2023
Mechanism of action
VEGFR inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 2018-09: Approved for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan, including those who have previously received anti-VEGF therapy and/or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type). (Based on FRESCO)
Also known as
- Code name: HMPL-013
- Brand name: Elunate